1. Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele Catania, Division of Cardiology, Centro Alte Specialità e Trapianti (CAST), Catania, Italy 2. Division of Cardiology, Poliiclinico-Vittorio Emanuele Hospital, C.A.S.T., University of Catania, Catania, Italy, ITALY 3. Division of Cardiology, Policlinico-Vittorio Emanuele Hospital, C.A.S.T., University of Catania, Catania, Italy 4. Division of Cardiac Surgery, Policlinico-Vittorio Emanuele Hospital, C.A.S.T., University of Catania, Catania, Italy 5. Division of Radiology, Policlinico-Vittorio Emanuele Hospital, C.A.S.T., Catania, Italy 6. Division of Vascular Surgery, Policlinico-Vittorio Emanuele Hospital, C.A.S.T., University of Catania, Catania, Italy
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Aim: To evaluate predictors and safety of next-day discharge (NDD) after transfemoral transcatheter aortic valve implantation (TF-TAVI) in unselected patients receiving either balloon- or self-expanding devices.
Methods and results: From June 2007 to August 2018, 1,232 consecutive patients undergoing TF-TAVI were discharged alive from our Institution. They had a mean age of 80.95.4 years and an intermediate estimated surgical mortality risk, and received either balloon-(26.1%) or self-expanding prostheses (73.9%). We compared patients discharged within 24 hours from the procedure (n=160,13.0%) with those discharged later, and accounted for confounding variables through a propensity matching adjustment.
After adjustment, no differences in all-cause mortality (1.2% vs. 0.0%, for NDD and no-NDD matched groups respectively, p=0.16) and permanent pacemaker implantation (PPI) after TAVI (0.6% vs. 0.6%) were encountered at 30 days. At 1 year, no difference in composite endpoint of all-cause death and heart failure (HF) rehospitalization was encountered (KM estimates 91.9% vs. 90.6% for NDD and no-NDD matched groups respectively, p=0.69). After excluding patients with post-procedural major complications from the unmatched population, prior PPI (OR:2.06; 95% CI:1.21-3.51; p<0.01) and availability of pre-procedural computed tomography angiography (CTA) (OR:1.71; CI:1.15-2.54; p<0.01) were found to be predictors of NDD after TAVI.
Conclusions: NDD in unselected patients after TF-TAVI using either balloon- or self-expanding devices demonstrated to be a safe strategy up to 1 year in absence of procedural complications. Patients with prior PPI and undergoing pre-procedural CTA had a higher chance of NDD.
Interventions for valvular diseaseTAVI
Join our mailing list
Sign up today to receive the weekly JAA's newsletter